Interview with Sandeep Gupta, Chairman and Managing Director, Eli Lilly and…
Having been director here in India between 1998-2002, and then again since 2006, you have clearly been in the front seat to observe the evolution of the Indian market. How…
Address: First Floor, Su Motor Complex,, Veena Nagar, Mulund West, Mumbai-400 080,India
Tel: 022 30781000
Web: http://truecare.in/Truecare/
Abbott is a diverse global health care company with scientific expertise and products that address the varied healthcare needs of the people.
Abbott has been present in India for over 100 years now starting operations in 1910. The company’s pharmaceutical offerings expanded significantly over the years through organic growth and acquisitions. Currently Abbott is India’s largest pharmaceutical company in 2010 with the acquisition of Knoll, Solvay pharmaceuticals and Piramal Healthcare (domestic formulations division)
The product portfolio in India can be categorized into three broad categories – Pharmaceuticals, Nutrition and Medical devices.
Abbott serves the evolving healthcare needs of Indian consumers by introducing products backed by strong R&D. In addition our Established Pharmaceuticals Division (EPD) offers an expanding portfolio of branded generic drugs.
Our global citizenship priorities address the principal economic, social and environmental challenges necessary for a healthy society and a favorable business environment.
With over 13,000 people, India is Abbott’s largest employee base outside the United States. The company seeks to attract, retain and develop the best talent to ensure a healthy, safe, fulfilling work environment for all employees in India.
The product portfolio in India can be categorized into three broad categories – Pharmaceuticals, Nutrition and Medical devices.
Abbott serves the evolving healthcare needs of Indian consumers by introducing products backed by strong R&D. In addition our Established Pharmaceuticals Division (EPD) offers an expanding portfolio of branded generic drugs.
Our global citizenship priorities address the principal economic, social and environmental challenges necessary for a healthy society and a favorable business environment.
Having been director here in India between 1998-2002, and then again since 2006, you have clearly been in the front seat to observe the evolution of the Indian market. How…
Looking back at the company’s recent challenges, we see a very tough 2009, largely due to the Betapharm acquisition and the subsequent changes in German regulations. How do you explain…
You have very successfully executed a vision that you have had for the company since it was a 200 Rs Cr turnover, India-focused enterprise 15 years ago. You have had…
When Astellas announced to expand its presence in India in 2009, you were already speaking of the company’s long commitment and solid relationship with India. Can you elaborate on these…
What probably best explains the contrasts in the Indian pharmaceutical landscape is the fact that India can take many shapes and forms and that different companies in India will keep…
For decades now, ACG has been building up its reputation in the global pharma space. The Indian Pharma industry, at the same time, increasingly is catching up with the Western…
For decades now, ACG has been building up its reputation in the global pharma space. The Indian Pharma industry, at the same time, increasingly is catching up with the Western…
You already joined the company in 2001, and returned after an MBA in the USA in 2004. This was also the time the company really took off, as you subsequently…
You already joined the company in 2001, and returned after an MBA in the USA in 2004. This was also the time the company really took off, as you subsequently…
Watson is one the largest generic players in the US but the international presence of the company is still relatively modest. Watson does not have commercial operations in India but…
You already joined the company in 2001, and returned after an MBA in the USA in 2004. This was also the time the company really took off, as you subsequently…
The managing director of Encube Ethicals discusses contract manufacturing in India today, growing competition from China, and partnering with the world’s leading multinational pharma companies. Mr Dilip Shah from…
See our Cookie Privacy Policy Here
